Condition (MeSH)
Vascular System Injuries
ClinicalTrials.gov lists 27 trials for Vascular System Injuries or a narrower condition beneath it. Humacyte, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
27 of the 27 trials are tagged with Vascular System Injuries itself; the rest are tagged with a narrower condition beneath it.
When did Vascular System Injuries trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 5 |
| 2013 | 2 |
| 2012 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vascular System Injuries trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 4 | 3 |
| Not applicable | 7 |
| Observational | 8 |
| Expanded access | 1 |
How many Vascular System Injuries trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Completed | 14 |
| Approved for marketing | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vascular System Injuries trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Humacyte, Inc. | 3 |
| Shire | 2 |
| United States Army Institute of Surgical Research | 1 |
Which drugs are being tested for Vascular System Injuries? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Acellular Tissue Engineered Vessel | 2 |
| LACTIC ACID (Dermacid) | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SRM003 | 2 |
| EC Aspirin | 1 |
| No ASA | 1 |
| Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV) | 1 |
| Low dose ASA | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Vascular System Injuries trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Vascular graft thrombosis | 12 | 1 |
| Acute myocardial infarction | 5 | 2 |
| Cardiac failure congestive | 5 | 3 |
| Fluid overload | 5 | 2 |
| Hyperkalaemia | 5 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Vascular System Injuries? (76)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bioengineered Human Arteries for the Repair of Vascular Injuries. | JAMA surgery | 2025 | Yes |
| Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. | Cardiovascular research | 2025 | Yes |
| A Randomized Comparison of Radial Artery Intimal Hyperplasia Following Distal Versus Proximal Transradial Access for Coronary Angiography: PRESERVE RADIAL. | Journal of the American Heart Association | 2024 | Yes |
| Early survival benefit of a low-profile endograft in blunt traumatic aortic injury. | Journal of vascular surgery | 2024 | Yes |
| Complications and Technical Consideration of Ultrasound-Guided Rectus Sheath Blocks: A Retrospective Analysis of 4033 Patients. | Anesthesia and analgesia | 2023 | Yes |
Showing 5 of 76 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.